Adaptive Biotechnologies (ADPT) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

T-Detect - T-Detect COVID: Enhance product profile with semi-quant data and correlate of protection[6, 41] - T-Detect AI: Increase sensitivity/specificity in MS, IBD, RA for market readiness[6, 41] - T-Detect most advanced indications include COVID (Only FDA authorized test, Medicare coverage for immunocompromised patients), AUTOIMMUNE (Clinical signals in five diseases: Crohn's, colitis, celiac, MS, RA), and LYME (Study Completed, Lyme season readiness)[16] Drug Discovery - Advance lead shared candidate to development with GNE collaboration[6, 41] - Deliver 2 fully characterized additional shared candidates with GNE collaboration[6, 41] - Develop private product prototype with GNE collaboration[6, 41] - Phase 1/2 data from Nykode collaboration[6, 41] MRD (Minimal Residual Disease) - Obtain Medicare coverage of DLBCL[6, 41] - Read-out data for use in blood in MM/DLBCL[6, 41] - Expand adoption of MRD status as a co-/primary clinical endpoint[6, 41] - MRD has evolved into an essential clinical decision-making tool[37] - Broad coverage for clonoSEQ: >240 million lives[35] - >$330 million in future regulatory milestones for clonoSEQ[35]